An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Leukemia

• Publication date

  2014-01-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/leu.2014.35PMID 24441292
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Masked polycythemia Vera (mPV): Results of an international study

  2014cited by this paper
• Rethinking the diagnostic criteria of polycythemia vera

  2014cited by this paper
• Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

  2014cited by this paper
• The molecular genetics of chronic neutrophilic leukaemia: defining a new era in diagnosis and therapy

  2014cited by this paper
• CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

  2014cited by this paper
• JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

  2014cited by this paper
• CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia

  2013cited by this paper
• Personalized management of essential thrombocythemia—application of recent evidence to clinical practice

  2013cited by this paper
• The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

  2013cited by this paper
• Mutations and prognosis in primary myelofibrosis

  2013cited by this paper
• Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

  2013cited by this paper
• Cardiovascular events and intensity of treatment in polycythemia vera.

  2013cited by this paper
• Somatic mutations of calreticulin in myeloproliferative neoplasms.

  2013cited by this paper
• Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

  2013cited by this paper
• Prevalence of a new auto-activating colony stimulating factor 3 receptor mutation (CSF3R-T595I) in acute myeloid leukemia and severe congenital neutropenia

  2013cited by this paper
• Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia

  2013cited by this paper
• Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis

  2013cited by this paper
• Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

  2013cited by this paper
• Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.

  2012cited by this paper
• NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.

  2011cited by this paper
• Concomitant occurrence of BCR-ABL and JAK2V617F mutation.

  2011cited by this paper
• Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS

  2011cited by this paper
• IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis

  2010cited by this paper
• An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia

  2009cited by this paper
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients

  2009cited by this paper
• Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera

  2007cited by this paper
• Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey.

  2007cited by this paper
• JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

  2007cited by this paper
• MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

  2006cited by this paper
• MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

  2006cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

  2005cited by this paper
• A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

  2005cited by this paper
• Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease

  2002cited by this paper
• An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia

  2002cited by this paper
• BCR-ABL transcripts may be detected in essential thrombocythemia but lack clinical significance.

  2001cited by this paper
• Calreticulin Is Essential for Cardiac Development

  1999cited by this paper
• Bone marrow histopathology in chronic myelogenous leukemia (CML)--evaluation of distinctive features with clinical impact.

  1999cited by this paper
• Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay.

  1994cited by this paper
• Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay

  1994cited by this paper

• Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification

  2025cites this paper
• CSF3R mutations and variants in myeloid neoplasms: associated phenotypes, co-mutations, and survival trends

  2025cites this paper
• Frequency of Calreticulin Genotype among JAK2V617F-negative Patients Suspected with Essential Thrombocythemia

  2024cites this paper
• Renal Extramedullary Hematopoiesis in Mast Cell Leukemia with Bone Marrow Fibrosis

  2024cites this paper
• Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms

  2024cites this paper
• Development and validation of a deep learning model for morphological assessment of myeloproliferative neoplasms using clinical data and digital pathology

  2024cites this paper
• Essential Thrombocythemia Possible Cause of Ischemic Cerebrovascular Disease: A Case Report

  2024cites this paper
• Emerging drug profile: JAK inhibitors

  2024cites this paper
• Essential Thrombocythemia and Ischemic Stroke: A Case Series of Five JAK2-Positive Patients

  2023cites this paper
• Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis

  2023cites this paper
• Presence of immune factors in freshwater mussel (Hyriopsis cumingii) entails autologous serum an essential component in the culture of mantle cells

  2023cites this paper
• Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group

  2023cites this paper
• Transformation of primary myelofibrosis into acute myeloblastic leukemia: clinical case

  2023cites this paper
• Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications

  2022cites this paper
• A case of CALR mutation in JAK2-negative patient with polycythemia

  2022cites this paper
• Inferring the initiation and development of myeloproliferative neoplasms

  2022cites this paper
• Calreticulin Immunohistochemistry in Myeloproliferative Neoplasms - Evolution of a New Cost-Effective Diagnostic Tool: A Retrospective Study with Histological and Molecular Correlation

  2021cites this paper
• Extramedullary Hematopoiesis of the Liver and Spleen

  2021cites this paper
• JAK2V617F, CALR and MPL515L/K mutations and plateletcrit in essential thrombocythemia: A single centre's experience

  2020cites this paper
• Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation

  2020cites this paper
• Hematopathology

  2020cites this paper
• Chronic Myelogenous Leukemia and Myeloproliferative Disorders in Older Adults

  2020cites this paper
• PCR đặc hiệu allele tích hợp công nghệ amplification refractory mutation system (Dsa-Pcr-Arms) phát hiện đột biến jak2 v617f và Carl trên bệnh nhân có hội chứng tăng sản tủy

  2020cites this paper
• Current management strategies for polycythemia vera and essential thrombocythemia.

  2020cites this paper
• КЛИНИКО-ГЕНЕТИЧЕСКИЕ ОСОБЕННОСТИ И ФАКТОРЫ ПРОГНОЗА ВЫЖИВАЕМОСТИ ПЕРВИЧНОГО МИЕЛОФИБРОЗА. ОБЗОР ЛИТЕРАТУРЫ.

  2020cites this paper
• Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis

  2020influential citation
• A case report and literature review

  2020influential citation
• Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms

  2020cites this paper
• Expanding the Classification of Leukemia by the World Health Organization over Time

  2019cites this paper
• MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease LCD

  2019cites this paper
• Diagnosis of Myeloproliferative Neoplasms: Current Perspectives from Recent Research

  2019cites this paper
• Treatment of myelodysplastic syndrome in the era of next‐generation sequencing

  2019cites this paper
• Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms

  2019cites this paper
• MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease Coverage Article

  2019cites this paper
• Recommendations for the diagnosis and treatment of patients with polycythaemia vera

  2018cites this paper
• A triplex probe-based TaqMan qPCR assay for Calreticulin type I and II mutation detection

  2018cites this paper
• Integrated computational biology analysis to evaluate target genes for chronic myelogenous leukemia.

  2018cites this paper
• Study of intracellular signaling pathways in Chronic Myeloproliferative Neoplasms

  2018cites this paper
• Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.

  2018cites this paper
• Major Changes to the 2017 Revision of the World Health Organization Classification of Myeloproliferative Neoplasms

  2018cites this paper
• Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

  2018cites this paper
• Ruxolitinib for the Treatment of Essential Thrombocythemia

  2018cites this paper
• [WHO classification of myeloid neoplasms].

  2018cites this paper
• The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera

  2018cites this paper
• Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms

  2018cites this paper
• Mutation profiling by targeted sequencing of “triple‐negative” essential thrombocythaemia patients

  2018cites this paper
• Parallel algorithm for myeloproliferative neoplasms testing: the frequency of double mutations is found in the JAK2/MPL genes more often than the JAK2/CALR genes, but is there a clinical benefit?

  2018cites this paper
• Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2

  2018influential citation
• Histological evaluation of myeloproliferative neoplasms.

  2018cites this paper
• Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis

  2018influential citation
• The WHO diagnostic criteria for polycythemia vera—role of red cell mass versus hemoglobin/hematocrit level and morphology

  2018cites this paper
• WHO-Klassifikation myeloischer Neoplasien

  2018cites this paper
• THE ROLE OF OXIDATIVE STRESS IN ESSENTIAL THROMBOCYTHEMIA

  2018cites this paper
• Peptide nucleic acid probe-based fluorescence melting curve analysis for rapid screening of common JAK2, MPL, and CALR mutations.

  2017cites this paper
• Natural and chemotherapy-induced clonal evolution of tumors

  2017cites this paper
• Genetic Polymorphisms of Hemostatic Factors and Thrombotic Risk in Non BCR-ABL Myeloproliferative Neoplasms: A Pilot Study

  2017cites this paper
• Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke.

  2017cites this paper
• Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia

  2017cites this paper
• Diagnostic anatomopathologique des néoplasies myéloprolifératives chroniques Ph

  2017cites this paper
• Genetic lesions and clinical implications in myeloproliferative neoplasms

  2017cites this paper
• Non-Classic Myeloproliferative Neoplasms: Are We Really Aware of These Rare Diseases in Daily Practice?

  2017cites this paper
• Molecular Testing in Myeloproliferative Neoplasms

  2017cites this paper
• Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease

  2017influential citation
• Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study

  2017cites this paper
• The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes

  2017cites this paper
• Acute megakaryoblastic transformation from essential thrombocythemia

  2017cites this paper
• Driver mutations in primary myelofibrosis and their implications

  2017cites this paper
• Local Coverage Determination ( LCD ) : MolDX : Genetic Testing for BCR-ABL Negative Myeloproliferative

  2017cites this paper
• Mutations in myeloproliferative neoplasms – their significance and clinical use

  2017cites this paper
• Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia.

  2017cites this paper
• Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia

  2016influential citation
• Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia

  2016cites this paper
• Myeloproliferative neoplasms: Morphology and clinical practice

  2016cites this paper
• JAK2、MPL和CALR基因突变在中国原发性骨髓纤维化患者中的预后意义

  2016cites this paper
• Evaluation and optimization of the extended information process unit (E-IPU) validation module integrating the sysmex flag systems and the recommendations of the French-speaking cellular hematology group (GFHC)

  2016cites this paper
• A CSF3R T618I Mutation in a Patient with Chronic Neutrophilic Leukemia and Severe Bleeding Complications.

  2016cites this paper
• 慢性中性粒细胞白血病合并多发性骨髓瘤二例报告并文献复习

  2016cites this paper
• Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.

  2016influential citation
• Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis

  2016cites this paper
• A novel assay to detect calreticulin mutations in myeloproliferative neoplasms

  2016cites this paper
• Case 37-2016. An 86-Year-Old Woman with Leukocytosis and Splenomegaly.

  2016cites this paper
• Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6–LYN gene fusion

  2016cites this paper
• The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances.

  2016cites this paper
• [Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis].

  2016cites this paper
• Molecular methodologies and molecular pathology of hematolymphoid neoplasms

  2016cites this paper
• Targeted deep sequencing in primary myelofibrosis.

  2016cites this paper
• Laboratory Investigation of Myeloproliferative Neoplasms (MPNs):  Recommendations of the Canadian Mpn Group.

  2016cites this paper
• CME Information: Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification and management

  2016cites this paper
• Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden

  2016cites this paper
• Biology of Myeloproliferative Malignancies

  2016cites this paper
• Treatment of Myelofibrosis: A Moving Target

  2016cites this paper
• Myeloproliferative neoplasms: A decade of discoveries and treatment advances

  2016cites this paper
• Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients

  2016cites this paper
• Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.

  2016cites this paper
• Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia

  2016cites this paper
• 《真性红细胞增多症诊断与治疗中国专家共识(2016年版)》解读

  2016cites this paper
• Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method

  2016cites this paper
• Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.

  2016cites this paper
• Treatment with Tyrosine Kinase Inhibitors in Chronic Myeloproliferative Neoplasms: Pros and Cons

  2016influential citation
• New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms

  2016influential citation